PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
van Rijt, S.H. ; Bölükbas, D.A.* ; Argyo, C.* ; Datz, S.* ; Lindner, M. ; Eickelberg, O. ; Königshoff, M. ; Bein, T.* ; Meiners, S.

Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors.

ACS Nano 9, 2377-2389 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Nanoparticles allow for controlled and targeted drug delivery to diseased tissues and therefore bypass systemic side effects. Spatiotemporal control of drug release can be achieved by nanocarriers that respond to elevated levels of disease-specific enzymes. For example, matrix metalloproteinase 9 (MMP9) is overexpressed in tumors, is known to enhance the metastatic potency of malignant cells, and has been associated with poor prognosis of lung cancer. Here, we report the synthesis of mesoporous silica nanoparticles (MSNs) tightly capped by avidin molecules via MMP9 sequence-specific linkers to allow for site-selective drug delivery in high-expressing MMP9 tumor areas. We provide proof-of-concept evidence for successful MMP9-triggered drug release from MSNs in human tumor cells and in mouse and human lung tumors using the novel technology of ex vivo 3D lung tissue cultures. This technique allows for translational testing of drug delivery strategies in diseased mouse and human tissue. Using this method we show MMP9-mediated release of cisplatin, which induced apoptotic cell death only in lung tumor regions of Kras mutant mice, without causing toxicity in tumor-free areas or in healthy mice. The MMP9-responsive nanoparticles also allowed for effective combinatorial drug delivery of cisplatin and proteasome inhibitor bortezomib, which had a synergistic effect on the (therapeutic) efficiency. Importantly, we demonstrate the feasibility of MMP9-controlled drug release in human lung tumors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.881
2.730
143
157
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bortezomib ; Cisplatin ; Combination Treatment ; Controlled Drug Delivery ; Ex Vivo 3d Lung Tissue Cultures ; Lung Cancer ; Matrix Metalloproteinase-9 ; Mesoporous Silica Nanoparticles ; Nanomedicine; Drug-delivery; Matrix Metalloproteinases; Poly(ethylene Glycol); Cancer Progression; In-vivo; Mmp-9; Adenocarcinoma; Bortezomib; Therapy; System
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 1936-0851
e-ISSN 1936-086X
Zeitschrift ACS Nano
Quellenangaben Band: 9, Heft: 3, Seiten: 2377-2389 Artikelnummer: , Supplement: ,
Verlag American Chemical Society (ACS)
Verlagsort Washington
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
German Center for Lung Research (DZL)
POF Topic(s) 30202 - Environmental Health
30503 - Chronic Diseases of the Lung and Allergies
80000 - German Center for Lung Research
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501600-004
G-505000-006
G-551800-001
G-501600-011
G-501800-806
G-501600-006
G-501600-001
PubMed ID 25703655
DOI 10.1021/nn5070343
WOS ID WOS:000351791800016
Erfassungsdatum 2015-03-27
[➜Korrektur melden]